Diabetic nephropathy (DN), also known as diabetic kidney disease, refers to kidney function damage caused by diabetes. DN is a leading cause of chronic kidney disease (CKD) and is associated with high morbidity, mortality, and healthcare cost. Use of pharmacotherapy for DN varies by disease severity, physician specialty, and CKD stage. Physicians consider management of DN challenging because current therapies manage only the complications of DN. Currently available therapies have limited efficacy and are unable to treat the underlying cause of the disease and prevent progressive renal decline in patients. This report investigates the current prescribing practices for DN and analyzes the various factors driving treatment decisions.
- Do treatment decisions for DN differ based on disease progression and the specialty of the treating physician?
- Which attributes are most important in choosing drugs for the management of DN patients?
- How do physicians perceive standard-of-care therapies such as angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for DN?
- What is the level of satisfaction among physicians with currently available DN treatments? What is the level of familiarity and interest in products in the development pipeline?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use, so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
- Diabetic Nephropathy - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment | Diabetic Nephropathy | US | September 2019
Author(s): Dwaipayan Chatterjee, M.Pharm
Dwaipayan Chatterjee is an Analyst in the Cardiovascular, Metabolism Renal and Hematology disease team at Decision Resources Group.
He holds a M.Pharm degree with specialization in Pharmaceutical Chemistry from Birla Institute of Technology & Science, Pilani, Rajasthan, India. Prior joining DRG, he worked as an Equity Analyst for the U.S. Healthcare sector with Market Realist working on competitive intelligence and analysis of pharmaceutical financial data. He also worked as a market research analyst for Mordor Intelligence with experience of market sizing, forecasting, and analyzing market dynamics.